The partners anticipate developing tests that analyze clusters of biomarkers to detect cardiovascular disease, kidney disease, liver cancer, and other diseases.
The kit is for quantitatively measuring the percent of glycated hemoglobin, total cholesterol, high-density lipoprotein, triglycerides, and glucose.
The new services geared toward wellness testing enable patients to order test kits without visiting their doctor.
The company's technology uses a drop of blood applied to a biochip to provide a "complete panel" of diagnostic test results within 15 minutes.
The firm said that the funding could boost the presence of its cardiovascular test already on the market in Europe and support the development of others.
The firm said that it will use the proceeds to roll out a fully automated point-of-care platform that enables use of a broad panel of acute blood biomarkers.
The test uses the same blood draw of a routine health exam and was designed to be unaffected biotin, a vitamin supplement that may skew some lab test results.
The financing will be used to further development of a handheld device, which is being designed to be used with a high-sensitivity troponin assay.
A high-sensitivity cardiac troponin T assay ruled out myocardial infarction in about 55 percent of patients within an hour, according to a new study.
The German company validated the panel, which focuses on actionable results, in a 300-participant clinical study in collaboration with Robert-Bosch-Hospital in Stuttgart.